


Please type a plus sign (+) inside this box →


PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT </div> <div style="text-align: center;">  <p>(use as many sheets as necessary)</p> </div>		<div style="text-align: right; font-weight: bold; font-size: 1.2em;"> Complete If Known RECEIVED </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">10/003,983</td> </tr> <tr> <td></td> <td style="text-align: right;">APR 25 2002</td> </tr> <tr> <td></td> <td style="text-align: right; font-weight: bold;">TECH CENTER 1600/2900</td> </tr> <tr> <td>Filing Date</td> <td>October 31, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Hans Josef Stauss</td> </tr> <tr> <td>Group Art Unit</td> <td>1645 - 1644</td> </tr> <tr> <td>Examiner Name</td> <td>M. DiBenedetto</td> </tr> <tr> <td>Attorney Docket Number</td> <td>ICI 103</td> </tr> </table>		Application Number	10/003,983		APR 25 2002		TECH CENTER 1600/2900	Filing Date	October 31, 2001	First Named Inventor	Hans Josef Stauss	Group Art Unit	1645 - 1644	Examiner Name	M. DiBenedetto	Attorney Docket Number	ICI 103
Application Number	10/003,983																		
	APR 25 2002																		
	TECH CENTER 1600/2900																		
Filing Date	October 31, 2001																		
First Named Inventor	Hans Josef Stauss																		
Group Art Unit	1645 - 1644																		
Examiner Name	M. DiBenedetto																		
Attorney Docket Number	ICI 103																		
Sheet 7 of 4	of	4																	

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office.*	Number ²	Kind Code ³ (if known)				
MO		WO	93/17095	A1	Scripps Research Institute	09-02-1993	X	
MO		WO	92/13887	A1	The Victoria University of Manchester	08-20-1992		
MO		WO	97/26328	A1	RPMS Technology Limited	07-24-1997		
act only MO		WO	00/02922	A1	Fuso Pharmaceutical Industries, Ltd	01-20-2000		
MO		WO	00/26249	A1	Imperial College Innovations Limited	05-11-2000		

Examine Signature		Date Considered	
-------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.**

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/003,983 APR 29 2002
		TECH CENTER 1600/2900	
Filing Date		October 31, 2001	
First Named Inventor		Hans Josef Stauss	
Group Art Unit		1645-1644	
Examiner Name		M. D. Bano	
Attorney Docket Number		ICI 103	
Sheet	2	of	4

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MD		AMROLIA, et al., "Nonmyeloablative stem cell transplantation for congenital immunodeficiencies," <i>Blood</i> 96(4):1239-1247 (2000).	
MD		CHUNG, et al., "Functional three-domain single-chain T-cell receptors," <i>Proc. Natl. Acad. Sci. USA</i> 91:12654-12658 (1994).	
MD		ELVIN, et al., "A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity," <i>J. Immunol. Methods</i> 158:161-171 (1993).	
MD		ESHAR, et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ξ subunits of the immunoglobulin and T-cell receptors," <i>Proc. Natl. Acad. Sci. USA</i> 90:720-724 (1993).	
MD		FINER, et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," <i>Blood</i> 83:43 (1994).	
MD		HANDGRETINGER, et al., "Transplantation of Megadoses of Purified Haploidentical Stem Cells," <i>Ann. NY Acad. Sci.</i> 897:351-361 (1999).	
MD		HWU, et al., "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor γ chain," <i>J. Exp. Med</i> 178:361-366 (1993).	
MD		JACKSON, et al., "Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in <i>Drosophila melanogaster</i> cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:12117 (1992).	
MD		CAST, et al., "Eradication of Adenovirus E1-Induced Tumors by E1A-Specific Cytotoxic T Lymphocytes," <i>Cell</i> 59:603-614 (1989).	
MD		KAWAKAMI, et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection," <i>Proc. Natl. Acad. Sci. USA</i> 91:6458-6462 (1994).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	5/2/02
----------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/003,983
		Filing Date	October 31, 2001
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1645-1644
		Examiner Name	M. D. Bano
		Attorney Docket Number	ICI 103

RECEIVED
APR 24 2002
TECH CENTER 1600/2900



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	(include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published)	T ²
MD		KIM, et al., "Introduction of Soluble Proteins into the MHC Class I Pathway by Conjugation to an HIV tat Peptide," <i>J. Immunol.</i> 159:1666-1668 (1997).	
MD		LJUNGGREN & KARRE, "Host Resistance Directed Selectively Against H-2-Deficient Lymphoma Variants," <i>J. Exp. Med.</i> 162:1745 (1985).	
MD		LU, et al., "Improved Synthesis of 4-Alkoxybenzyl Alcohol Resin," <i>J. Org. Chem.</i> 46:3433 (1981).	
MD		MÉZIÈRE, et al., "In Vivo T Helper Cell Response to Retro-Inverso Peptidomimetics," <i>J. Immunol.</i> 159:3230-3237 (1997).	
MD		MORITZ, et al., "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:4318-4322 (1994).	
MD		MOTTEZ, et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic," <i>J. Exp. Med.</i> 181:493-502 (1995).	
MD		PORTA, et al., "Development of Cowpea Mosaic Virus as a High-Yielding System for the Presentation of Foreign Peptides," <i>Virology</i> 202:449-955 (1994).	
MD		ROBERTS, et al., "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8 T Lymphocytes Armed With Universal T-Cell Receptors," <i>Blood</i> 84:2878-2889 (1994).	
MD		SAIKI, et al., "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," <i>Science</i> 239:487-491 (1988).	
MD		<i>The Leukocyte Antigen Fact Book</i> , 2 nd edition, "CD45: Leucocyte common antigen (L-CA), B220, T200, Ly-5, EC 3.1.3.48," pp. 244-247, Academic Press, Harcourt, Brace & Co. (publishers), 1997.	


Examiner's Signature	Marianne D. Bano	Date Considered	5/2/02
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
		RECEIVED			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/003,983		
		Filing Date	October 31, 2001		
		First Named Inventor	Hans Josef Stauss		
		Group Art Unit	1645-1644		
		Examiner Name	M. DiBano		
Sheet	4	of	4	Attorney Docket Number	ICI 103

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MD		TOURDOT, et al., "Chimeric Peptides: A New Approach to Enhancing the Immunogenicity of Peptides with Low MHC Class I Affinity," <i>J. Immunol.</i> 159:2391-2398 (1997).	
MD		WILSON, et al., "Immunogenicity. I. Use of Peptide Libraries to Identify Epitopes That Activate Clonotypic CD4 T Cells and Induce T Cell Responses to Native Peptide Ligands," <i>J. Immunol.</i> 163:6424-6434 (1999).	

Examiner's Signature	<i>Marianne DiBano</i>	Date Considered	5/2/05
----------------------	------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+